{"originalText": "2014年2月在当地行左侧卵巢癌手术，两侧附件及子宫切除，术后病理见卵巢癌及淋巴结转移，局部无放疗，已行化疗，手术后予以6周期脂质体紫杉醇+卡铂，化疗中因腹膜后淋巴结肿大尔后予以THP2周期。近期于2015年3月3日查B超见腹膜后淋巴结转移，盆腔无复发。2015-3-12始行第1周期吉西他滨+顺铂，具体：吉西他滨1000MG/M2 1.6G D1，D8 +顺铂40MG/M2 66MG D1，D8 Q21D。用药后皮肤瘙痒，给予抗过敏治疗。3月19行第1周期第8天治疗。因药物过敏，于2015年4月2日予以第2周期GP化疗，具体同第1周期.拟于4月23日予以2周期化疗复查。2周期疗效短径缩小总疗效SD(短径缩小)，故于2015年4月27日予以GP+恩度治疗，拟于2015-5-18日行复查腹部CT疗效为SD（较一个月前略变平，余病灶无变化），改为TAMOXIFEN治疗+腹膜后淋巴结放疗。", "entities": [{"label_type": "手术", "overlap": 0, "start_pos": 11, "end_pos": 28}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 34, "end_pos": 43}, {"end_pos": 69, "label_type": "药物", "overlap": 0, "start_pos": 63}, {"end_pos": 72, "label_type": "药物", "overlap": 0, "start_pos": 70}, {"end_pos": 83, "label_type": "解剖部位", "overlap": 0, "start_pos": 77}, {"end_pos": 92, "label_type": "药物", "overlap": 0, "start_pos": 89}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 112, "end_pos": 120}, {"end_pos": 123, "label_type": "解剖部位", "overlap": 0, "start_pos": 121}, {"end_pos": 146, "label_type": "药物", "overlap": 0, "start_pos": 142}, {"end_pos": 149, "label_type": "药物", "overlap": 0, "start_pos": 147}, {"end_pos": 157, "label_type": "药物", "overlap": 0, "start_pos": 153}, {"end_pos": 181, "label_type": "药物", "overlap": 0, "start_pos": 179}, {"end_pos": 328, "label_type": "药物", "overlap": 0, "start_pos": 326}, {"label_type": "影像检查", "overlap": 0, "start_pos": 346, "end_pos": 350}, {"end_pos": 384, "label_type": "药物", "overlap": 0, "start_pos": 375}, {"end_pos": 393, "label_type": "解剖部位", "overlap": 0, "start_pos": 387}]}
